
Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Your AI-Trained Oncology Knowledge Connection!


Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Published: April 26th 2011 | Updated:

Published: April 29th 2011 | Updated:

Published: May 5th 2011 | Updated: